close

Agreements

Date: 2011-12-20

Type of information:

Compound: new cancer therapeutics

Company: Affibody (Sweden) Nuclisome (Sweden)

Therapeutic area: Cancer Oncology

Type agreement: R&D

Action mechanism:

Disease: cancer

Details: Affibody AB and Nuclisome AB have announced a collaboration agreement with the aim of developing new cancer therapeutics. The companies will combine their respective technologies to create potent anti-cancer treatments for patients that are currently underserved by conventional therapy. Affibody® molecules are a novel class of antibody mimetics that are excellent payload carriers and may also have potential efficacy, safety, and administration route benefits. In addition, Affibody® molecules have been proven as targeting agents together with liposomes. 
The Nuclisome concept utilizes liposomal carriers in combination with a two-step targeting principle, and aims at the delivery of Auger-electron emitting radionuclides to the nucleus of tumor cells. Low energy Auger-electron emitters, such as 125I, are very potent in causing complex double-strand breaks in DNA In the novel Nuclisome approach double-strand breaks is achieved by utilizing a specially designed compound that binds very strongly to DNA.  The high specificity and remarkable potency of the Nuclisome approach, make Nuclisome-particles interesting for several clinical indications. Results obtained to date suggest that treatment with Nuclisome-particles has the potential to become an effective therapy against metastasizing cancer cells in several diseases such as breast and ovarian cancer

Financial terms: Financial details were not disclosed.

Latest news:

Is general: Yes